



T3D

MINT IT. PRINT IT.

ASX ANNOUNCEMENT

14 October 2025

Appendix 4C and Quarterly Activities Report

The Board of Directors of 333D Ltd (ASX:T3D or “**Company**”) releases its cash flow report (**Appendix 4C**) for the quarter ending 30 September 2025 (“**the quarter**”) and provides an update on activities during the quarter.

QUARTERLY ACTIVITIES REPORT

Principal Activities

333D Limited is a company that seeks to capitalise upon opportunities in the digital line of business as new technologies are developed from both digital capture and digital creation perspectives, that will lend themselves for use in a myriad of interfaces, both physical (3D printed) and/or across other or additional digital platforms. 333D specialises in the digital capture of a subject matter; digital creation of data files incorporating diagnostic or medical imaging in DICOM format, 2D, 3D and animated digital content including still photography, digital design and motion video; and encoding data files using artificial intelligence such that a digitally created file is generated that is viewable in a 3D format and capable of being printed by a 3D printer. 333D Limited also provides bespoke design and management of digital assets (including 3D print files) and bespoke 3D printing bureau services.

Key areas of activity during the quarter

The Company continued to receive licence and services fees from its digital asset management contracts generating \$318,431 in cash receipts from customers. This represents the fifth consecutive quarter of growth with an increase of 15.69% compared to the previous quarter. These results continues to demonstrate the value of the Company’s strategic shift in providing digital asset management services to the healthcare sector.

Since announcing the radiology pilot program on 31 July 2024, the Company has delivered more than \$1 million in incremental revenue and invested more than \$600,000 on its highly scalable digital asset management SaaS platform.

During the quarter, the Company also received an R&D Tax Incentive of \$413,773 from the Australian Taxation Office as a result of the Company’s continuing research and development activities.

The net operating cash received from operating activities for the quarter was \$160,742, compared to \$85 cash used from last quarter.

Placement raising \$1 million from sophisticated investors

During the quarter the Company completed a placement to sophisticated investors raising \$1,000,000 in capital at an issue price of \$0.10 per share. The costs of the offer were \$30,000 with the net proceeds of the issue of shares being \$970,000 during the quarter.

333D Limited

ABN 24 118 159 881

Level 23, Rialto South Tower,
525 Collins Street,
Melbourne VIC 3000 Australia





Summary of expenditure incurred

Expenditure during the quarter was approximately \$571,463. The expenditure incurred and reported in the Appendix 4C during the quarter comprised;

▪ product manufacturing and operating costs	\$142,211
▪ staff cost	\$ 27,936
▪ administration and corporate costs	\$401,316

Bitcoin treasury

In addition to the expenditure above, and as announced on 25 August 2025, the Company acquired 2.01830401 Bitcoin pursuant to the *Bitcoin Treasury Management Policy*, that allows for cash in excess of the working capital requirements to be used towards building a long-term strategic holding of Bitcoin, to support future acquisitions and growth initiatives by the Company.

The current value of the Bitcoin holding is AUD\$356,784. In addition to this long-term strategic holding of Bitcoin, and as reported at Item 5.5 (Cash and cash equivalents) in the *Appendix 4C*, the Company has a cash balance of \$835,508.

Payments to related parties

Pursuant to *ASX Listing Rule 4.7C.3*, the Company made payments to related parties during the quarter of \$41,905. This included \$27,574 in reimbursements for expenses incurred on behalf of the Company to entities related to Director Dr Nigel Finch and \$14,331 in reimbursements for expenses to entities related to Director Mr John Conidi.

Events subsequent to the quarter

As announced on 6 October 2025, the Company has entered into a pilot collaboration agreement with BioScan 360 to provide its services in the burgeoning preventative healthcare market. The Company will record vital data from full body MRI scans on the Blockchain allowing decentralised storage and handing secure, auditable ownership of the data back to the patient. Based on the performance of the pilot, the Company will look to expand this service nationally.

During the quarter the Directors attended international conferences on Bitcoin, artificial intelligence and digital assets including, among others, *Bitcoin Asia 2025* in Hong Kong and *TOKEN2049* in Singapore. The purpose was to build upon the Company's knowledge relating to risk management, technology applications and provide valuable networking opportunities with potential investors and partners.

Interested investors are encouraged to follow the Company's X (formerly Twitter) account for more information on the Company's conference and keynote presentations at x.com/333D_co.

The Company has been invited to present at the *Australian Crypto Convention* on 22-23 November 2025 at the International Convention Centre in Sydney. At this convention T3D will be part of a panel discussion that includes Strategy Inc. CEO Phong Le.

The Company has also been invited to attend the Cantor Fitzgerald *Crypto & AI/Energy Infrastructure Conference* on 10-12 November in Miami.

The 2025 Annual General Meeting of the Company will be held on Thursday 20 November at 11:00 AM (Melbourne time). Please refer to the ASX announcement on 25 September for further details.

Use of Funds Statement

The Company confirms that the quarter is not included in a period covered by a "use of funds" statement or expenditure program in a prospectus, PDS or information memorandum previously lodged under *ASX Listing Rule 1.1*.



- END -

The release of this announcement was **authorised by the Board of Directors** of the Company.

About 333D Limited

333D Limited is a company that seeks to capitalise upon opportunities in the digital line of business as new technologies are developed from both digital capture and digital creation perspectives, that will lend themselves for use in a myriad of interfaces, both physical (3D printed) and/or across other or additional digital platforms. 333D specialises in the digital capture of a subject matter; digital creation of data files incorporating diagnostic or medical imaging in DICOM format, 2D, 3D and animated digital content including still photography, digital design and motion video; and encoding data files using artificial intelligence such that a digitally created file is generated that is viewable in a 3D format and capable of being printed by a 3D printer. 333D Limited also provides bespoke design and management of digital assets (including 3D print files) and bespoke 3D printing bureau services.

To find out more about 333D visit 333D.co

For further enquiries please contact:

John Conidi - Executive Chairman
+61 (0) 411 773 101
john@333d.co

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

333D Limited

ABN

26 118 159 881

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows		Current quarter \$A	Year to date (3 months) \$A
1. Cash flows from operating activities			
1.1 Receipts from customers		318,431	318,431
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		-142,211	-142,211
(c) advertising and marketing		-	-
(d) leased assets		-	-
(e) staff costs		-27,936	-27,936
(f) administration and corporate costs		-401,316	-401,316
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		1	1
1.5 Interest and other costs of finance paid		-	-
1.6 Income taxes paid		-	-
1.7 Government grants and tax incentives		413,773	413,773
1.8 Other (provide details if material)		-	-
1.9 Net cash from operating activities		160,742	160,742
2. Cash flows from investing activities			
2.1 Payments to acquire:			
(a) entities		-	-
(b) businesses		-	-
(c) property, plant and equipment		-	-
(d) investments		-370,500	-370,500
(e) intellectual property		-	-
(f) other non-current assets		-	-

Consolidated statement of cash flows		Current quarter \$A	Year to date (3 months) \$A
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash used in investing activities	-370,500	-370,500

3.	Cash flows from financing activities		
3.1	Proceeds from issues of share capital	970,000	970,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from financing activities	970,000	970,000

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	75,266	75,266
4.2	Net cash from / (used in) operating activities (item 1.9 above)	160,742	160,742
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-370,500	-370,500
4.4	Net cash from / (used in) financing activities (item 3.10 above)	970,000	970,000

Consolidated statement of cash flows		Current quarter \$A	Year to date (3 months) \$A
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	835,508	835,508

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A	Previous quarter \$A
5.1	Bank balances	835,508	75,266
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	835,508	75,266

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

Current quarter \$A
41,905
-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Payments to related parties during the quarter totalled \$41,905. This included \$27,574 in reimbursements for expenses incurred on behalf of the Company to entities related to Director Dr Nigel Finch and \$14,331 in reimbursements for expenses to entities related to Director Mr John Conidi.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amount at quarter end \$A	Amount drawn at quarter end \$A
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-

7.5 **Unused financing facilities available at quarter end** -

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A
8.1 Net cash from / (used in) operating activities (Item 1.9)	160,742
8.2 Cash and cash equivalents at quarter end (Item 4.6)	835,508
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	835,508
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	N/A

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **14 October 2025**



Authorised by: **Dr Nigel Finch, Director**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.